Please login to the form below

Not currently logged in
Email:
Password:

Ranbaxy wins approval for generic analgesics

India-headquartered Ranbaxy Pharmaceuticals (RPI) has won FDA approval to manufacture and market two analgesic drugs.

India-headquartered Ranbaxy Pharmaceuticals (RPI) has won FDA approval to manufacture and market two analgesic drugs.

The FDA approval permits Ranbaxy to produce different dosages of hydrocodone bitartrate and acetaminophen for the treatment of moderate to moderately severe pain.

The approved drugs are bio-equivalent copies of Norco, Vicodin and Lortab, the annual market sales of which were USD 391m.

Jim Meehan, vice-president of sales and marketing for RPI, said: "These approvals further expand our product portfolio of affordable generic alternatives and will be launched in a November 2007 time period."

21st August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...
image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...

Infographics